Floatz logo

Anti-Cd19/22-Car Vector-Transduced T Cells

Recurrent Grade 1 Follicular Lymphoma

Chinese PLA General HospitalCell therapyPhase 1/2Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
89/ 100

Competitive context

21 Active assets in the Recurrent Grade 1 Follicular Lymphoma cohort.

Asset / SponsorPhaseRating
CYCLOSPORIN A
Fred Hutchinson Cancer Center
Phase 2/3BBB
Romidepsin
City of Hope Medical Center
Phase 2BBB
Irinotecan
University of Michigan Rogel Cancer Center
Phase 2BBB
Busulphan
Masonic Cancer Center, University of Minnesota
Phase 2/3BBB
ETOPOSIDE
David Bond, MD
Phase 3BB

View all 50 →

Same molecule, other indications

Anti-Cd19/22-Car Vector-Transduced T Cells is also rated in:

Hematopoietic/Lymphoid CancerDormant
CCC
Indicative ·
48 / 100
View asset →
B-Cell Chronic Lymphocytic Leukemia in Relapse (Diagnosis)Dormant
CCC
Indicative ·
48 / 100
View asset →
B-cell Adult Acute Lymphoblastic LeukemiaDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →